Acrux History

ACRUX TIMELINE

1998

Acrux incorporated

2001

First US patent granted

2003

Veterinary licensed to Elanco globally (including Recuvyra®)

2004

Acrux listed on ASX (ACR:ASX)

2007

Evamist® licensed to KV Pharmaceutical in US

2008

Evamist® launched by KV Pharmaceutical

Acrux initiates Axiron® Phase III clinical trial

2010

Acrux submits Axiron® NDA to FDA

Axiron® licensed to Eli Lilly globally

2011

Axiron® launched by Eli Lilly

2013

Recuvyra® launched by Elanco

Estradiol licensed to Gedeon Richter; including for EU

2014

Evamist® licensed to Perrigo in US

2015

Initiated generic programs

2016

Lenzetto® launched in Europe

2017

Active pipeline of 10 generic products.

Axiron® was withdrawn from the US market on 5th of September 2017 due to the launch of generic versions.

2018

Submitted first two ANDA (generic) products to the FDA for review

2019

Submitted third ANDA (generic) product to the FDA for review.

Active pipeline of 14 generic products.